Logo image of IPHA

INNATE PHARMA SA-SPONS ADR (IPHA) Stock Fundamental Analysis

NASDAQ:IPHA - Nasdaq - US45781K2042 - ADR - Currency: USD

1.7751  -0.01 (-0.83%)

Fundamental Rating

2

Overall IPHA gets a fundamental rating of 2 out of 10. We evaluated IPHA against 558 industry peers in the Biotechnology industry. IPHA has a bad profitability rating. Also its financial health evaluation is rather negative. IPHA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IPHA had negative earnings in the past year.
In the past year IPHA has reported a negative cash flow from operations.
IPHA had negative earnings in each of the past 5 years.
In the past 5 years IPHA always reported negative operating cash flow.
IPHA Yearly Net Income VS EBIT VS OCF VS FCFIPHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

1.2 Ratios

IPHA has a Return On Assets (-44.54%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -560.01%, IPHA is doing worse than 79.03% of the companies in the same industry.
Industry RankSector Rank
ROA -44.54%
ROE -560.01%
ROIC N/A
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
IPHA Yearly ROA, ROE, ROICIPHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IPHA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IPHA Yearly Profit, Operating, Gross MarginsIPHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IPHA has been increased compared to 1 year ago.
Compared to 5 years ago, IPHA has more shares outstanding
IPHA has a worse debt/assets ratio than last year.
IPHA Yearly Shares OutstandingIPHA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPHA Yearly Total Debt VS Total AssetsIPHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

IPHA has an Altman-Z score of -4.88. This is a bad value and indicates that IPHA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.88, IPHA is not doing good in the industry: 60.22% of the companies in the same industry are doing better.
IPHA has a Debt/Equity ratio of 8.02. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 8.02, IPHA is not doing good in the industry: 84.05% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 8.02
Debt/FCF N/A
Altman-Z -4.88
ROIC/WACCN/A
WACC7.13%
IPHA Yearly LT Debt VS Equity VS FCFIPHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

IPHA has a Current Ratio of 2.60. This indicates that IPHA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.60, IPHA is not doing good in the industry: 69.00% of the companies in the same industry are doing better.
IPHA has a Quick Ratio of 2.60. This indicates that IPHA is financially healthy and has no problem in meeting its short term obligations.
IPHA's Quick ratio of 2.60 is on the low side compared to the rest of the industry. IPHA is outperformed by 67.03% of its industry peers.
Industry RankSector Rank
Current Ratio 2.6
Quick Ratio 2.6
IPHA Yearly Current Assets VS Current LiabilitesIPHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

IPHA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -549.63%.
Looking at the last year, IPHA shows a very negative growth in Revenue. The Revenue has decreased by -75.68% in the last year.
The Revenue for IPHA have been decreasing by -28.80% on average. This is quite bad
EPS 1Y (TTM)-549.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.49%
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-73.85%

3.2 Future

The Earnings Per Share is expected to decrease by -14.00% on average over the next years. This is quite bad
The Revenue is expected to grow by 43.06% on average over the next years. This is a very strong growth
EPS Next Y121.73%
EPS Next 2Y75.86%
EPS Next 3Y-14%
EPS Next 5YN/A
Revenue Next Year86.96%
Revenue Next 2Y85.05%
Revenue Next 3Y29.35%
Revenue Next 5Y43.06%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IPHA Yearly Revenue VS EstimatesIPHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
IPHA Yearly EPS VS EstimatesIPHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IPHA. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 19.50, which indicates a rather expensive current valuation of IPHA.
Based on the Price/Forward Earnings ratio, IPHA is valued cheaply inside the industry as 92.83% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 21.29. IPHA is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 19.5
IPHA Price Earnings VS Forward Price EarningsIPHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPHA Per share dataIPHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A cheap valuation may be justified as IPHA's earnings are expected to decrease with -14.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y75.86%
EPS Next 3Y-14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IPHA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNATE PHARMA SA-SPONS ADR

NASDAQ:IPHA (6/25/2025, 8:00:02 PM)

1.7751

-0.01 (-0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)09-17 2025-09-17
Inst Owners10.09%
Inst Owner Change15.92%
Ins Owners2.18%
Ins Owner ChangeN/A
Market Cap163.59M
Analysts78.18
Price Target6.08 (242.52%)
Short Float %0.09%
Short Ratio2.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.66%
PT rev (3m)15.78%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)161.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 19.5
P/S 11.17
P/FCF N/A
P/OCF N/A
P/B 15.95
P/tB 15.95
EV/EBITDA N/A
EPS(TTM)-0.62
EYN/A
EPS(NY)0.09
Fwd EY5.13%
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.16
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.54%
ROE -560.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 8.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.61%
Cap/Sales 3.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.6
Quick Ratio 2.6
Altman-Z -4.88
F-Score1
WACC7.13%
ROIC/WACCN/A
Cap/Depr(3y)22.77%
Cap/Depr(5y)23.45%
Cap/Sales(3y)3.3%
Cap/Sales(5y)8.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-549.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.49%
EPS Next Y121.73%
EPS Next 2Y75.86%
EPS Next 3Y-14%
EPS Next 5YN/A
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-73.85%
Revenue Next Year86.96%
Revenue Next 2Y85.05%
Revenue Next 3Y29.35%
Revenue Next 5Y43.06%
EBIT growth 1Y-307.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.78%
EBIT Next 3Y30.44%
EBIT Next 5YN/A
FCF growth 1Y79.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.82%
OCF growth 3YN/A
OCF growth 5YN/A